Although a KRAS mutation confers resistance to panitumumab, a human monoclonal antibody against epidermal growth factor receptor in colorectal cancer [89], oncogenic KRAS mutations may be sensitive to mitogen-activated protein kinase kinase (MEK) inhibitors in other solid tumors [91], including ovarian cancer [92]. This evidence concerns the gene KRAS and ovarian carcinoma.